Omeros | OMER - Gross Profit On Sales


Omeros reported $-33.16M in Gross Profit on Sales for its fiscal quarter ending in June of 2024.





Gross Profit On Sales Change Date
Adma Biologics USD 88.82M 13.19M Dec/2025
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Cytokinetics USD 17.76M 15.82M Dec/2025
Gilead Sciences USD 6.31B 106M Dec/2025
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Immunic 0 0 Mar/2025
Insmed USD 217.69M 106.25M Dec/2025
Knight Therapeutics CAD 64.72M 8.91M Dec/2025
MacroGenics USD 31.11M 30.14M Dec/2025
Omeros USD -33.16M 18.52M Jun/2024
Pacira USD 126.64M 15.61M Mar/2026
Pfizer USD 12.28B 8.74B Dec/2025
Rockwell Medical USD 4.55M 1.49M Jun/2024
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
United Therapeutics USD 315.5M 286.6M Dec/2025
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026
Xoma 992K 846K Jun/2024